A Phase I, Randomized, Double-blind, Placebo-controlled, Single-dose, Dose-escalation Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profiles of AK0406 in Healthy Adult Participants
Latest Information Update: 03 Mar 2026
At a glance
- Drugs AK 0406 (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions; First in man
- Sponsors Ark Biosciences
Most Recent Events
- 03 Mar 2026 New trial record